Jeffrey Weber on the Role of Oncology Nurses in Treating Patients With Checkpoint Inhibitors
Jeffrey Weber, MD, PhD, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, discusses the role of the oncology nurse when treating patients who have cancer with checkpoint inhibitors.
Jeffrey Weber, MD, PhD, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, discusses the role of the oncology nurse when treating patients who have cancer with checkpoint inhibitors.
Nurses are typically the “first line of defense,” Weber said, as they are often are the first ones to hear about how patients are feeling; thus, it is crucial for oncology nurses to know what to look for regarding adverse events when treating patients who are on checkpoint inhibitors.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
